
Women who cut short their
Tamoxifen treatment before the recommended full five years risk their
breast cancer returning, experts warn.
Tamoxifen is used to treat tumours fuelled by the female hormone oestrogen
Up to half of women stop taking the drug prematurely but in
doing so significantly reduce their survival odds, says Cancer Research
UK.
Data shows for every hundred women who complete the full course, six fewer will have a recurrence of their cancer.
Tamoxifen is usually given to women with oestrogen-sensitive breast cancer.
This means that their tumour's growth is fed by the female hormone, and tamoxifen can help by blocking oestrogen.
But the treatment can cause unpleasant side effects like...